Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. ishizuk@shinshu-u.ac.jp
Osamu
O
Ishizuka
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy*
D058668:Adrenergic alpha-1 Receptor Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil